Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.46−0.28 (-4.15%)
Close on Nov 20, 2026Market cap $422.40MP/E 40.4Yield –
Arvinas shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Arvinas's shares outstanding was 66M at Jun 30, 2026. For fiscal 2025 it was 71M, down 1.4% from the year before. The highest annual figure on record is 72M in fiscal 2024.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 71M | -1.4% |
| FY2024 | Dec 31, 2024 | 72M | +29.5% |
| FY2023 | Dec 31, 2023 | 56M | +4.3% |
| FY2022 | Dec 31, 2022 | 53M | +6.4% |
| FY2021 | Dec 31, 2021 | 50M | +26.6% |
| FY2020 | Dec 31, 2020 | 40M | +20.1% |
| FY2019 | Dec 31, 2019 | 33M | +249.2% |
| FY2018 | Dec 31, 2018 | 9M | +396.6% |
| FY2017 | Dec 31, 2017 | 2M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 66M | -10.0% |
| Q1 FY2026 | Mar 31, 2026 | 64M | -12.0% |
| Q4 FY2025 | Dec 31, 2025 | 65M | -9.7% |
| Q3 FY2025 | Sep 30, 2025 | 73M | +1.5% |
| Q2 FY2025 | Jun 30, 2025 | 73M | +1.5% |
| Q1 FY2025 | Mar 31, 2025 | 73M | +1.4% |
| Q4 FY2024 | Dec 31, 2024 | 72M | +17.5% |
| Q3 FY2024 | Sep 30, 2024 | 72M | +33.3% |
| Q2 FY2024 | Jun 30, 2024 | 72M | +34.6% |
| Q1 FY2024 | Mar 31, 2024 | 72M | +34.5% |
| Q4 FY2023 | Dec 31, 2023 | 61M | +14.4% |
| Q3 FY2023 | Sep 30, 2023 | 54M | +1.7% |
| Q2 FY2023 | Jun 30, 2023 | 53M | +0.4% |
| Q1 FY2023 | Mar 31, 2023 | 53M | +0.6% |
| Q4 FY2022 | Dec 31, 2022 | 54M | +1.5% |
| Q3 FY2022 | Sep 30, 2022 | 53M | +6.8% |
| Q2 FY2022 | Jun 30, 2022 | 53M | +8.8% |
| Q1 FY2022 | Mar 31, 2022 | 53M | +9.1% |
| Q4 FY2021 | Dec 31, 2021 | 53M | +26.5% |
| Q3 FY2021 | Sep 30, 2021 | 50M | +27.5% |
| Q2 FY2021 | Jun 30, 2021 | 49M | +26.2% |
| Q1 FY2021 | Mar 31, 2021 | 49M | +26.1% |
| Q4 FY2020 | Dec 31, 2020 | 42M | +11.5% |
| Q3 FY2020 | Sep 30, 2020 | 39M | +19.3% |
| Q2 FY2020 | Jun 30, 2020 | 39M | +23.2% |
| Q1 FY2020 | Mar 31, 2020 | 39M | +23.1% |
| Q4 FY2019 | Dec 31, 2019 | 37M | +20.1% |
| Q3 FY2019 | Sep 30, 2019 | 33M | +1528.2% |
| Q2 FY2019 | Jun 30, 2019 | 31M | +1556.9% |
| Q1 FY2019 | Mar 31, 2019 | 31M | +1550.8% |
| Q4 FY2018 | Dec 31, 2018 | 31M | +1538.9% |
| Q3 FY2018 | Sep 30, 2018 | 2M | +6.0% |
| Q2 FY2018 | Jun 30, 2018 | 2M | 0.0% |
| Q1 FY2018 | Mar 31, 2018 | 2M | 0.0% |
| Q4 FY2017 | Dec 31, 2017 | 2M | – |
| Q3 FY2017 | Sep 30, 2017 | 2M | – |
| Q2 FY2017 | Jun 30, 2017 | 2M | – |
| Q1 FY2017 | Mar 31, 2017 | 2M | – |
See a number that looks wrong?